Updated Jul 16, 2026
Kaseta Michael has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $15.93M.
Michael Kaseta is a corporate executive known for his roles as CFO and COO at Liquidia Corp and Heron Therapeutics, Inc. He has been involved in the biopharmaceutical industry, focusing on the development of treatments for pulmonary hypertension.
| Role | CFO and COO |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 19.0K | $71.52 | $1.36M |
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 1.5K | $71.39 | $104K |
| 2026-07-15 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 7.0K | — | |
| 2026-07-15 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 5.8K | — | |
| 2026-04-17 | LQDA | Liquidia Corp | S — Open-market sale | 43.4K | $40.14 | $1.74M |
| 2026-04-17 | LQDA | Liquidia Corp | S — Open-market sale | 87.0K | $40.14 | $3.49M |
| 2026-04-17 | LQDA | Liquidia Corp | M — Option exercise | 87.0K | $2.79 | $243K |
| 2026-04-17 | LQDA | Liquidia Corp | S — Open-market sale | 9.0K | $40.14 | $363K |
| 2026-04-17 | LQDA | Liquidia Corp | S — Open-market sale | 3.0K | $40.00 | $120K |
| 2026-04-17 | LQDA | Liquidia Corp | M — Option exercise | 3.0K | $2.79 | $8K |
| 2026-04-14 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 19.0K | $38.37 | $727K |
| 2026-04-14 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 7.0K | — | |
| 2026-04-14 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 5.8K | — | |
| 2026-04-14 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 23.8K | $40.14 | $956K |
| 2026-04-14 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 23.8K | $2.79 | $66K |
| 2026-04-13 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 133.8K | $40.24 | $5.38M |
| 2026-04-13 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 9.3K | $2.54 | $24K |
| 2026-04-13 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 728 | $2.54 | $2K |
| 2026-04-13 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 18.1K | $2.97 | $54K |
| 2026-04-13 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 86.6K | $2.79 | $242K |
Michael Kaseta is a corporate executive known for his roles as CFO and COO at Liquidia Corp and Heron Therapeutics, Inc. He has been involved in the biopharmaceutical industry, focusing on the development of treatments for pulmonary hypertension.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 17 open-market sales ($15.93M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Kaseta Michael profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.